In this discussion, Dr Tanenbaum and Suzie Bash, MD, a Medical Director at RadNet in Los Angeles, cover the intersection of disease-modifying therapies (DMTs), quantitative imaging, and artificial intelligence (AI) in managing Alzheimer disease.

In this discussion, Dr Tanenbaum, Ana Franceschi, MD, associate professor of radiology at Lenox Hill Hospital, Hofstra/Northwell in New York City; and Adam Samchuck, senior product manager for PET Solutions at Siemens Healthineers, North America, explore the evolving role of molecular imaging in Alzheimer disease (AD) diagnosis, as well as the impact of emerging AD therapeutics.

In this discussion, Dr Tanenbaum, Tammie L.S. Benzinger, MD, PhD, a professor of radiology who serves as chief of MRI service at Mallinckrodt Institute of Radiology at Washington University School of Medicine in St. Louis, Missouri, and Saurabh Sharma, MBA, a senior director for MR Strategy at Siemens Healthineers, explore whether imaging enterprises are prepared for the expected growth in the demand for brain MR imaging in patients with Alzheimer disease.